| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148374 | BRISTOL-MYERS SQUIBB | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039718 | BRISTOL-MYERS SQUIBB | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(9 years from now) | |
Evotaz is owned by Bristol-Myers Squibb.
Evotaz contains Atazanavir Sulfate; Cobicistat.
Evotaz has a total of 2 drug patents out of which 0 drug patents have expired.
Evotaz was authorised for market use on 29 January, 2015.
Evotaz is available in tablet;oral dosage forms.
Evotaz can be used as treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.
The generics of Evotaz are possible to be released after 06 October, 2032.
Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient
Market Authorisation Date: 29 January, 2015
Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET;ORAL
EVOTAZ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic